Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

IMPORTANCE: Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering improved survival outcomes are therefore needed. OBJECT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Shroff, Rachna T., Javle, Milind M., Xiao, Lianchun, Kaseb, Ahmed O., Varadhachary, Gauri R., Wolff, Robert A., Raghav, Kanwal P. S., Iwasaki, Michiko, Masci, Peter, Ramanathan, Ramesh K., Ahn, Daniel H., Bekaii-Saab, Tanios S., Borad, Mitesh J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567834/
https://ncbi.nlm.nih.gov/pubmed/30998813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0270
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados